Tissue-agnostic cancer drug

From WikiMD's Wellness Encyclopedia

Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear.[1][2][3] Tissue-agnostic drugs include Pembrolizumab (Keytruda) and Larotrectinib (Vitrakvi).[2] [4]

History[edit | edit source]

Petrolizumab was approved by the US Food and Drug Administration In May 2017.[5]

Larotrectinib was approved by the FDA in November, 2018.[5]

Loxo-292 received priority review in September 2018.[5]

Other drugs under development include Entrectinib, BLU-667, Loxo-195 and Anti-ERBB3 antibody.[5]

References[edit | edit source]

  1. 2.0 2.1
  2. 5.0 5.1 5.2 5.3 Wang, Brian (June 19, 2019). "New Gene Targeting Cancer Drugs And Other Advances in Cancer Medicine – NextBigFuture.com". www.nextbigfuture.com. Retrieved 2019-06-19. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)


Tissue-agnostic cancer drug Resources

Contributors: Prab R. Tumpati, MD